ACR Meeting Abstracts

ACR Meeting Abstracts

  • Meetings
    • ACR Convergence 2024
    • ACR Convergence 2023
    • 2023 ACR/ARP PRSYM
    • ACR Convergence 2022
    • ACR Convergence 2021
    • ACR Convergence 2020
    • 2020 ACR/ARP PRSYM
    • 2019 ACR/ARP Annual Meeting
    • 2018-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • View and print all favorites
    • Clear all your favorites
  • ACR Meetings

Abstract Number: 335

Treatment with Bgp-15, a Novel Insulin Sensitizer Attenuates Collagen-Induced Arthritis in DBA/1 Mice

Peter Mandl1, Silvia Hayer2, Stephan Blüml3, Victoria Saferding1, Despoina Sykoutri1, Kurt Redlich2 and Josef S. Smolen4, 1Rheumatology, Medical University of Vienna, Vienna, Austria, 2Department of Internal Medicine III, Division of Rheumatology, Medical University of Vienna, Vienna, Austria, 3Department of Rheumatology, Medical University of Vienna, Vienna, Austria, 4Department of Rheumatology, Medical University of Vienna and Hietzing Hospital, Vienna, Austria

Meeting: 2012 ACR/ARHP Annual Meeting

Keywords: Animal models, heat-shock proteins and inflammatory arthritis

  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print
Session Information

Title: Rheumatoid Arthritis: Animal Models

Session Type: Abstract Submissions (ACR)

Background/Purpose:

BGP-15, a small synthetic hydroxylamine derivative is a member of a new class of insulin-sensitizing medications also known as chaperone-inducers. Beside its beneficial effects on glycemic control and insulin sensitivity in patients with Type 2 diabetes, BGP-15 is known to induce heat shock protein Hsp72 and heat shock transcription factor HSF1, which in turn are involved in joint inflammation. Moreover, BGP-15 also inhibits poly-ADP-ribose polymerase (PARP) and the phosphorylation of c-JUN N-terminal kinase via Hsp72 overexpression. Therefore it might also play a role in the regulation of inflammatory joint disease. Our objective was to evaluate the in vivo effects of BGP-15 on collagen-induced arthritis (CIA) in DBA/1 mice.

Methods:

Arthritis was induced by intradermal injection of bovine type II collagen (bCII) and incomplete Freund’s adjuvant (CFA) in male DBA/1 mice. BGP-15 was administered either one week prior to the first immunization (prophylactic experiment, n:14 in both groups) or upon the appearance of symptoms (therapeutic experiment, n:12 in both groups) in drinking water. Arthritis incidence and severity was assessed for 28 days following the second immunization (boost) with bCII and CFA on day 21. Histological evaluation was carried out on hind paws using Osteomeasure® software. Anticollagen antibodies were measured by enzyme-linked immunosorbent assay. The cellular composition of the draining lymph nodes was measured by flow cytometry. In vitrocytokine measurements were carried out on dendritic cells and macrophages differentiated from murine bone marrow macrophages.

Results:

BGP-15 significantly reduced the incidence of CIA by 28% and also reduced both paw swelling (p≤0.01) and grip strength (p≤0.05) in the prophylactic experiment. In the therapeutic experiment BGP-15 significantly attenuated both paw swelling (p≤0.01) and grip strength (p≤0.05). Histological evaluation of the hind paws demonstrated reduced area of inflammation (p≤0.05), area of erosion (p≤0.01) and number of osteoclasts (p≤0.05) in the BGP-15 treated group when compared to the control group. No significant differences were revealed between anticollagen antibody levels or in the distribution of T-cells, B-cells, dendritic cells and monocytes/macrophages harvested from draining lymph nodes, suggesting an effect predominantly involving the innate immune system. In line with these findings BGP-15 (1mM) inhibited the LPS-induced production of IL-12, IL-6 and TNF in both dendritic cells and macrophages.

Conclusion:

Our results demonstrate that the novel chaperone-inducer BGP-15 has a profound prophylactic and therapeutic effect on autoimmune arthritis, mainly due to an effect on the effector phase.


Disclosure:

P. Mandl,
None;

S. Hayer,
None;

S. Blüml,
None;

V. Saferding,
None;

D. Sykoutri,
None;

K. Redlich,
None;

J. S. Smolen,
None.

  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print

« Back to 2012 ACR/ARHP Annual Meeting

ACR Meeting Abstracts - https://acrabstracts.org/abstract/treatment-with-bgp-15-a-novel-insulin-sensitizer-attenuates-collagen-induced-arthritis-in-dba1-mice/

Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

Wiley

  • Online Journal
  • Privacy Policy
  • Permissions Policies
  • Cookie Preferences

© Copyright 2025 American College of Rheumatology